

Lundberg E<sup>1</sup>, Kriström B<sup>1</sup>, Holmlund M<sup>1</sup>, Albertsson Wikland K<sup>2</sup>

<sup>1</sup>Dep of Clinical Science/Pediatrics, Umeå University, <sup>2</sup>Dep of Physiology/Endocrinology, Institute of Neurosciences and Physiology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.

P2-220


**Aim:** By mimicking normal pubertal physiology induce breast development, pubertal height gain and increase adult height in children with multiple pituitary hormone deficiencies (MPHD)

**Background:** Pubertal tempo of breast development on natural sex-steroid replacement therapy in girls with MPHD and pubertal growth spurts on adequate GH-treatment regimens were unknown in 1989 and are still not known.

**Study population and treatment:** Six girls with organic or idiopathic MPHD with at least one prepubertal year on GH 33µg/kg/day, were randomized to receive GH (Genotropin®) 33 or 67µg/kg/day during puberty. Sex-steroid replacement was 17β-estradiol patches in slowly increasing doses (5, 10, 12.5, 25, 50µg/day) mimicking the spontaneous pubertal tempo<sup>1</sup>. For this purpose, pharmaceutical 17β-estradiol patches (Estraderm®) were produced and donated.

## Results

Breast development in girls with MPHD on therapy vs healthy girls<sup>1</sup>



Breast development in girls with MPHD on therapy. Median age for each breast stage (blue line) compared to normal values according to Tanner<sup>1</sup> (broken line).

Median age and duration of breast stages in girls with MPHD on therapy vs healthy girls<sup>1</sup>

Total (n)	Stage	Age (y)	Range (y)	Mean values Tanner (y)
6	B2	13.5	12.9-14.4	11.15
6	B3	14.4	13.4-15.6	12.15
6	B4	16.5	14.6-17.6	13.11
4	B5	18.2	15.6-19.2	15.33
Total (n)	Interval	Duration (y)	Range (y)	Mean values Tanner (y)
6	B2-B3	1.2	0.8-1.7	0.86
6	B3-B4	1.8	0.5-4.0	0.89
4	B4-B5	1.5	1.0-3.1	1.96
6	B2-B4	3.0	1.7-4.2	1.80
4	B2-B5	4.3	2.7-5.5	4.00

Median age and duration of breast stages in girls with MPHD, receiving increasing doses of transdermal estradiol replacement compared to Tanner<sup>1</sup> mean values from healthy girls.

elena.lundberg@umu.se


ESPE Vienna 2019

## Conclusion

- Tempo of breast development, pubertal growth spurt and adult height can be normalized in MPHD girls by using a physiological substitution therapy with transdermal 17β-estradiol and adequate GH-doses.

- This allows earlier age for pubertal induction.

## GH-study design




## Height methods and outcome

Pubertal height gain was estimated as change from height<sub>SDS</sub> at start of 17β-estradiol-replacement (calculated vs prepubertal height reference) to Adult Height.

**Pubertal gain in height<sub>SDS</sub> was median +0.8 (0 to 1.15); in cm 21.1 (11.8-21.6).**

AH<sub>SDS</sub> median 0.075 (-1.33 to 0.31); in cm 168.0 (159.5 to 169.5).

Adult height in girls with MPHD vs mean population height for girls<sup>2</sup>



Filled circles: GH dose 67 µg/kg/day. Open circle: GH 33 µg/kg/day. Mean population height for females in Sweden is 167.7 cm<sup>2</sup> (broken line)

## Referenser

<sup>1</sup>Marshall&Tanner, Arch. Dis.Child.1969;44:291-303

<sup>2</sup>Albertsson-Wikland et al Acta Ped 2002;91:739-54